Castle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences (Nasdaq: CSTL), a company specializing in innovative health tests, has announced its participation in two upcoming investor conferences. The company's executive management will present a company overview at Baird's 2024 Global Healthcare Conference on September 11, 2024, at 9:05 a.m. Eastern time. A live audio webcast of this presentation will be available on Castle Biosciences' website, with a replay accessible afterwards.
Additionally, Castle Biosciences will be available for one-on-one investor meetings during the 8th Annual Lake Street Best Ideas Growth (BIG8) Conference on September 12, 2024. Interested parties can request meetings exclusively through Lake Street Capital Markets. These conferences provide opportunities for investors to gain insights into Castle Biosciences' operations and future plans.
Castle Biosciences (Nasdaq: CSTL), un'azienda specializzata in test sanitari innovativi, ha annunciato la sua partecipazione a due imminenti conferenze per investitori. La direzione esecutiva dell'azienda presenterà una panoramica della società alla Conferenza sanitaria globale Baird 2024 il 11 settembre 2024, alle 9:05 ore orientali. Una trasmissione audio in diretta di questa presentazione sarà disponibile sul sito web di Castle Biosciences, con una registrazione accessibile in un secondo momento.
Inoltre, Castle Biosciences sarà disponibile per incontri individuali con gli investitori durante la 8ª Conferenza annuale Lake Street Best Ideas Growth (BIG8) il 12 settembre 2024. Le parti interessate possono richiedere riunioni esclusivamente tramite Lake Street Capital Markets. Queste conferenze offrono opportunità agli investitori per ottenere informazioni sulle operazioni e i piani futuri di Castle Biosciences.
Castle Biosciences (Nasdaq: CSTL), una empresa especializada en pruebas de salud innovadoras, ha anunciado su participación en dos próximas conferencias para inversores. La dirección ejecutiva de la empresa presentará una visión general de la compañía en la Conferencia de atención médica global de Baird 2024 el 11 de septiembre de 2024, a las 9:05 a.m. hora del este. Una transmisión de audio en vivo de esta presentación estará disponible en el sitio web de Castle Biosciences, con una repetición accesible posteriormente.
Adicionalmente, Castle Biosciences estará disponible para reuniones individuales con inversores durante la 8ª Conferencia Anual Lake Street Best Ideas Growth (BIG8) el 12 de septiembre de 2024. Las partes interesadas pueden solicitar reuniones exclusivamente a través de Lake Street Capital Markets. Estas conferencias ofrecen oportunidades a los inversores para obtener información sobre las operaciones y planes futuros de Castle Biosciences.
캐슬 바이오사이언스(Castle Biosciences)(Nasdaq: CSTL)는 혁신적인 건강 검사의 전문 기업으로, 다가오는 두 가지 투자자 회의에 참여할 것임을 발표했습니다. 회사의 경영진은 2024년 9월 11일 오전 9시 5분 동부 표준시(Eastern time)에 Baird의 2024 글로벌 헬스케어 회의에서 회사 개요를 발표할 예정입니다. 이 발표의 실시간 오디오 웹캐스트는 캐슬 바이오사이언스의 웹사이트에서 제공되며, 이후 다시 볼 수 있습니다.
또한, 캐슬 바이오사이언스는 2024년 9월 12일 열리는 제8회 레이크 스트리트 최고의 아이디어 성장 회의(BIG8) 동안 일대일 투자자 미팅을 진행할 예정입니다. 관심 있는 분들은 레이크 스트리트 캐피탈 마켓을 통해서만 미팅을 요청할 수 있습니다. 이러한 회의는 투자자들이 캐슬 바이오사이언스의 운영과 향후 계획에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
Castle Biosciences (Nasdaq: CSTL), une entreprise spécialisée dans les tests de santé innovants, a annoncé sa participation à deux conférences pour investisseurs à venir. La direction de l'entreprise présentera un aperçu de la société lors de la Conférence globale sur la santé de Baird 2024 le 11 septembre 2024 à 9h05, heure de l'Est. Un webinaire audio en direct de cette présentation sera disponible sur le site web de Castle Biosciences, avec un rediffusion accessible par la suite.
De plus, Castle Biosciences sera disponible pour des réunions individuelles avec des investisseurs lors de la 8ème Conférence annuelle Lake Street Best Ideas Growth (BIG8) le 12 septembre 2024. Les parties intéressées peuvent demander des réunions exclusivement par l'intermédiaire de Lake Street Capital Markets. Ces conférences offrent aux investisseurs des opportunités d'obtenir des informations sur les opérations et les plans futurs de Castle Biosciences.
Castle Biosciences (Nasdaq: CSTL), ein Unternehmen, das sich auf innovative Gesundheitstests spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Management des Unternehmens wird am 11. September 2024 um 9:05 Uhr Eastern Time eine Unternehmensübersicht auf der Baird's 2024 Global Healthcare Conference präsentieren. Ein Live-Audio-Webcast dieser Präsentation wird auf der Website von Castle Biosciences verfügbar sein, mit einer anschließenden Wiederholung.
Zusätzlich wird Castle Biosciences am 12. September 2024 für eins-zu-eins-Investorenmeetings während der 8. jährlichen Lake Street Best Ideas Growth (BIG8) Konferenz verfügbar sein. Interessierte Parteien können Meetings ausschließlich über Lake Street Capital Markets anfordern. Diese Konferenzen bieten Investoren die Möglichkeit, Einblicke in die Geschäftsabläufe und zukünftigen Pläne von Castle Biosciences zu gewinnen.
- None.
- None.
A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be available following the conclusion of the live broadcast.
Castle will also be available for one-on-one investor meetings during the 8th Annual Lake Street Best Ideas Growth (BIG8) Conference on Sept. 12, 2024. Meetings may be requested exclusively through Lake Street Capital Markets.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828537095/en/
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
FAQ
When is Castle Biosciences (CSTL) presenting at Baird's 2024 Global Healthcare Conference?
How can investors access Castle Biosciences' (CSTL) presentation at Baird's conference?
Is Castle Biosciences (CSTL) participating in the 8th Annual Lake Street Best Ideas Growth Conference?
How can investors request meetings with Castle Biosciences (CSTL) at the Lake Street conference?
